地诺单抗推荐剂量

Recommended dosage: Different dosages are given for different indications. Bone metastases from solid tumors: 120 mg subcutaneously in the upper arm, thigh, or abdomen every 4 weeks. Giant cell tumor of bone: 120 mg subcutaneously every 4 weeks, followed by 120 mg on days 8 and 15 during the first month of treatment. Administer calcium and vitamin D appropriately to prevent hypocalcemia. Malignant hypercalcemia: 20 mg subcutaneously every 4 weeks, followed by 120 mg on days 8 and 15 during the first month of treatment. The medication is injected under the skin in the upper arm, thigh, or abdomen. Medical companions remind: Denosumab can only be injected subcutaneously, not intravenously, intramuscularly or intradermally.

Denosumab is a fully humanized monoclonal antibody (IgG2 monoclonal antibody) that specifically targets receptor activator of nuclear factor-κB ligand (RANKL). It blocks the binding of RANKL to its receptor substances, diverts osteoclast activation and development, reduces bone resorption, and increases bone density. It can effectively inhibit multinucleated giant cells in giant cell tumors of bone. After a certain period of imaging, the bone formation increase is evaluated. Pathological examination shows that the number of multinucleated giant cells is significantly reduced or disappears).

It is mainly used to treat giant cell tumors of bone in adults and adolescents with mature skeletal development. Indications include patients who cannot be surgically resected or whose surgical resection may cause severe disability and metastasis. It can also be used for metastatic cancer and osteoporosis.

Clinical research results: A phase II clinical study of 282 cases showed that 96% of patients who could not be cured by surgery did not progress within a median time of 13 months after use. 100 patients initially required high-level surgical treatment. After 9.2 months of treatment with denosumab, 74 patients no longer needed surgical treatment, and 16 of the remaining 26 patients underwent low-level surgical treatment. (In short: denosumab drug treatment is effective for most patients, can control disease progression, and achieve surgical downgrading (reduce the difficulty of surgery); for giant cell tumors of bone in complex anatomical locations, denosumab may increase surrounding tissue adhesion; its long-term effect still needs further investigation).